セファロスポリン薬のヨーロッパ市場2019-2025

【英語タイトル】Europe Cephalosporin Drugs Market (2019-2025)

KBV Researchが出版した調査資料(KBV9DE348)・商品コード:KBV9DE348
・発行会社(調査会社):KBV Research
・発行日:2019年7月
・ページ数:118
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:ヨーロッパ
・産業分野:産業未分類
◆販売価格オプション(消費税別)
Single User(1名様利用)USD1,500 ⇒換算¥165,000見積依頼/購入/質問フォーム
Site Licence(法人利用)USD2,520 ⇒換算¥277,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

The Europe Cephalosporin Drugs Market would witness market growth of 2.94% CAGR during the forecast period (2019–2025).Cephalosporin Drugs is a bactericidal, wide-spectrum, β-lactam antibiotic initially extracted from the Acremonium fungus that is used to treat bacterial diseases such as pneumonia, skin diseases, tonsillitis, otitis media, bronchitis, gonorrhea, and others. It is similar to penicillin and is, therefore, used as an option to penicillin-allergic patients.
Developing extremely effective and secure Cephalosporin Drugs, growing mergers and corporate acquisitions to manufacturing these drugs are likely to create growth opportunities for the market for Cephalosporin Drugs in the coming years. On the other hand, low R&D investment and rigid public policies on these medicines hamper the market growth.
Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.
Scope of the Study
Market Segmentation:
By Generation
• First-Generation Cephalosporin
• Second-Generation Cephalosporin
• Third-Generation Cephalosporin
• Fourth-Generation Cephalosporin
• Fifth-Generation Cephalosporin
By Application
• Respiratory Tract Infection
• Skin Infection
• Ear Infection
• Sexually Transmitted Infection
• Others
By Route of Administration
• Injections
• Oral Drugs
By Type
• Branded
• Generic
By Country
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe
Companies Profiled
• ABBOTT Laboratories
• Teva Pharmaceuticals Industries Ltd.
• Johnson and Johnson
• GlaxoSmithKline PLC (GSK)
• Pfizer, Inc.
• Merck & Co., Inc.
• Bayer AG
• Baxter International, Inc.
• BRISTOL-MYERS SQUIBB COMPANY
• Novartis AG
Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

【レポートの目次】

Table of Contents: Europe Cephalosporin Drugs Market
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Cephalosporin Drugs Market, by Generation
1.4.2 Europe Cephalosporin Drugs Market, by Application
1.4.3 Europe Cephalosporin Drugs Market, by Route of Administration
1.4.4 Europe Cephalosporin Drugs Market, by Type
1.4.5 Europe Cephalosporin Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Cephalosporin Drugs Market by Generation
3.1 Europe First-Generation Cephalosporin Drugs Market by Country
3.2 Europe Second-Generation Cephalosporin Drugs Market by Country
3.3 Europe Third-Generation Cephalosporin Drugs Market by Country
3.4 Europe Fourth-Generation Cephalosporin Drugs Market by Country
3.5 Europe Fifth-Generation Cephalosporin Drugs Market by Country
Chapter 4. Europe Cephalosporin Drugs Market by Application
4.1 Europe Respiratory Tract Infection Market by Country
4.2 Europe Skin Infection Market by Country
4.3 Europe Ear Infection Market by Country
4.4 Europe Sexually Transmitted Infection Market by Country
4.5 Europe Others Market by Country
Chapter 5. Europe Cephalosporin Drugs Market by Route of Administration
5.1 Europe Injections Market by Country
5.2 Europe Oral Drugs Market by Country
Chapter 6. Europe Cephalosporin Drugs Market by Type
6.1 Europe Branded Market by Country
6.2 Europe Generic Market by Country
Chapter 7. Europe Cephalosporin Drugs Market by Country
7.1 Germany Cephalosporin Drugs Market
7.1.1 Germany Cephalosporin Drugs Market by Generation
7.1.2 Germany Cephalosporin Drugs Market by Application
7.1.3 Germany Cephalosporin Drugs Market by Route of Administration
7.1.4 Germany Cephalosporin Drugs Market by Type
7.2 UK Cephalosporin Drugs Market
7.2.1 UK Cephalosporin Drugs Market by Generation
7.2.2 UK Cephalosporin Drugs Market by Application
7.2.3 UK Cephalosporin Drugs Market by Route of Administration
7.2.4 UK Cephalosporin Drugs Market by Type
7.3 France Cephalosporin Drugs Market
7.3.1 France Cephalosporin Drugs Market by Generation
7.3.2 France Cephalosporin Drugs Market by Application
7.3.3 France Cephalosporin Drugs Market by Route of Administration
7.3.4 France Cephalosporin Drugs Market by Type
7.4 Russia Cephalosporin Drugs Market
7.4.1 Russia Cephalosporin Drugs Market by Generation
7.4.2 Russia Cephalosporin Drugs Market by Application
7.4.3 Russia Cephalosporin Drugs Market by Route of Administration
7.4.4 Russia Cephalosporin Drugs Market by Type
7.5 Spain Cephalosporin Drugs Market
7.5.1 Spain Cephalosporin Drugs Market by Generation
7.5.2 Spain Cephalosporin Drugs Market by Application
7.5.3 Spain Cephalosporin Drugs Market by Route of Administration
7.5.4 Spain Cephalosporin Drugs Market by Type
7.6 Italy Cephalosporin Drugs Market
7.6.1 Italy Cephalosporin Drugs Market by Generation
7.6.2 Italy Cephalosporin Drugs Market by Application
7.6.3 Italy Cephalosporin Drugs Market by Route of Administration
7.6.4 Italy Cephalosporin Drugs Market by Type
7.7 Rest of Europe Cephalosporin Drugs Market
7.7.1 Rest of Europe Cephalosporin Drugs Market by Generation
7.7.2 Rest of Europe Cephalosporin Drugs Market by Application
7.7.3 Rest of Europe Cephalosporin Drugs Market by Route of Administration
7.7.4 Rest of Europe Cephalosporin Drugs Market by Type
Chapter 8. Company Profiles
8.1 ABBOTT Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.1 Recent strategies and developments:
8.1.1.1 Collaborations, partnerships and agreements:
8.1.1.2 Acquisition and Mergers:
8.2 Teva Pharmaceutical Industries Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Product launches:
8.3 Johnson and Johnson
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental &Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 GlaxoSmithKline PLC (GSK)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Collaborations, partnerships and agreements:
8.4.5.2 Expansion:
8.4.5.3 Approval:
8.5 Pfizer, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Collaborations, partnerships and agreements:
8.5.5.2 Product launches:
8.5.5.3 Acquisition and Mergers:
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Collaborations, partnerships and agreements:
8.6.5.2 Product launches:
8.7 Bayer AG (Bayer Schering Pharma AG)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Collaborations, partnerships and agreements:
8.7.5.2 Product launches:
8.8 Baxter International, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Product launches:
8.9 Bristol-Myers Squibb Company
8.9.1 Company overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Collaborations, partnerships and agreements:
8.1 Novartis AG
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Product launches:
8.10.5.2 Acquisition and Mergers:



★調査レポート[セファロスポリン薬のヨーロッパ市場2019-2025] (コード:KBV9DE348)販売に関する免責事項を必ずご確認ください。
★調査レポート[セファロスポリン薬のヨーロッパ市場2019-2025]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆